XTL Biopharmaceuticals Ltd. reported significant financial losses of $5.5 million for the six months ending June 30, 2025, attributed to a write-down of its subsidiary's assets following executive resignations and related disputes. This filing also notes a revenue of $517,000 due to consolidation from the subsidiary, which began on August 14, 2024.